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Abstract 
Severe sepsis and septic shock are major causes of morbidity and mortality in 
intensive care units worldwide, accounting for 250,000 deaths each year in the United 
States alone. Sepsis is the clinical manifestation of a dysregulated innate immune 
response to microbial infection. Over-activation of inflammatory mediators may result in 
multiple organ failure, acute circulatory failure, and death. Recognition of non-self 
microbial products by host cell receptors is fundamental to the innate inflammatory 
response. CD14 is a general pattern recognition receptor that is responsible for sensitive 
detection of many unique pathogen-associated toxins such as LPS, PGN, and LTA. The 
structure and function of CD14 has extensive implications in understanding the innate 
immune response and progression of the potentially fatal syndrome sepsis . However, no 
structural data of CD14 has been acquired; the nature of its interactions with endotoxins 
has yet to be characterized. Production of milligram quantities of protein is necessary for 
NMR structural studies of CD14. This paper discusses the endotoxin-induced innate 
response, treatment strategies for sepsis, and gives a protocol for the expression and 
purification of a 152 amino acid fragment of soluble CD14. 
Background 
Sepsis 
Sepsis is a condition involving an out of control host systematic inflammatory 
response caused by the infection of pathogenic micro-organisms in humans. As the 
condition progresses, it can lead to multiple organ dysfunction 'severe sepsis', and even 
to a state of acute circulatory failure characterized by arterial hypotension 'septic shock' 
and death (Levy et a\., 2003). Sepsis is the tenth most common cause of death in the 
United States-affecting approximately 750,000 patients annually and accounting for 
over 210,000 deaths per year (Hoyert et a!., 2001; Angus et aI., 2001). With the incidence 
of sepsis rising at rates between 1.5-8% per year despite technical improvements made 
in intensive care units (ICUs), and costs of approximately $16.7 billion per year 
burdening the US health care system, massive research efforts have been undertaken in 
search of improved treatments and therapy(Martin et aI., 2003). 
It is the innate immune response that is the first line of defense when a pathogen 
crosses the host's natural defense barriers, however, it is the over-activation of the innate 
immune system that is directly responsible for the deleterious symptoms of sepsis. 
Leukocytes play an important role, recognizing the pathogens and eliciting inflammatory 
initiators. The release of proinflammatory mediators, such as chemokines and cytokines 
facilitates the migration of serum-soluble components out of the vasculature and into the 
specific area where the microbial invasion has been detected (Glauser et a!., 1991; 
Mirlashari & Lyberg, 2003; Dentener et aI., 1993). This response is essential for effective 
combat of host microbial infection. 
In septic shock, the endotoxin-induced over-synthesis of pro-inflamatory 
cytokines and chemokines, IL-l, IL-6, IL-8, IL-12, and TNF-a, and over-activation of 
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macrophages results in the release of toxic molecules from polymorphonuclear celJs. 
These processes trigger the further production of cytokines and endothelial necrosis, 
resulting in coagulatory responses and multiple complex proteolytic cascades 
(Riedemann et aI., 2003). This self-amplifying and dysregulated inflammatroy response 
often leads to organ failure and mortality, if not curtailed by counter-regulatory systems 
and anti-inflammatory cytokines (Baumgartner & Calandra, 1999). 
Endotoxins LPS & PGN 
There are several components associated with pathogens that the immune defense 
system engages for detection and initiation of inflammatory response. Of the bacterial 
components commonly exploited by the immune system are lipopolysaccharide (LPS), 
peptidoglycan (PGN), lipotechoic acid (LTA), lipoarabinomannan (LAM), lipoprotein 
and unmethylated DNA with CpG motif. LPS is present in large quantities on the surface 
of Gram-negative bacteria, while PGN and LTA are important components of Gram-
positive bacteria, though all three reside at low levels on the outer surfaces of both types 
of cells. 
Although other bacterial components are recognized by the innate immune 
response system, LPS and PGN form the two major bacterial endotoxin components 
recognized by innate defenses. The outer protectant on the membrane of Gram-negative 
bacteria is constituted, in large part, of the phosphoglycolipid LPS (Joiner, 1988). The 
lipid A moiety of LPS (Fig. 1) is highly hydrophopic and tethers one end of the endotoxin 
within the phospholipid bilayer allowing the O-region of LPS to form a perimeter of 
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defense on the extracellular surface, thwarting the actions of bile salts and hydrophobic 
antibiotics (Backhed, 2003). 
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acetylmuramic acid cross-linked by short peptides 
(Fig. 1), is an essential component of the cell wall of 
Gram-positive bacteria (Schleifer & Kandler, 1972; 
Doyle & Dziarsky, 2001). The PON polymers 
surround the membrane in bacteria and are responsible 
for maintaining the cel1ular shape and withstanding 
the force created by the osmotic gradient of the 
bacteria and the surrounding environment. LPS and 
PGN are necessary for bacterial vitality and are released 
during cell growth and death. 
CD14 Human Endotoxin Receptor 
Figure 1. Molecular motifs recognized by 
CD14: Lipid A Moiety of LPS & 
PGN repeating units. 
The human endotoxin receptor CD14 is in the vanguard of the host innate 
immune defenses. Responsible for detection of endotoxins at subnanomolar 
concentrations, CD14 is a pattern recognition receptor that detects unique pathogen-
associated molecular motifs (Wright et aI., 1990). The 55 kDa 
glycosyJphosphatidyJinositol (OPI)-anchored protein is expressed on the membrane-
surfaces of monocytes and macrophages and is critical for early mobilization of innate 
defenses and activation of anti-microbial pathways (Haziot et al. 1998; Lee et aI., 1992; 
Weidemann et aI., 1994). CD14 is also expressed as a soluble form (sCD14) lacking the 
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GPI anchor at concentrations of 2-6 Il-g/ml in human serum. Soluble CD14 acts to 
reconnoiter and activate responses to endotoxin in endothelial, epithelial, and other cells 
devoid of the membrane-bound form (mCD14) (Grunwald et aI., 1992; Pugin et aI., 1993; 
Frey et aI., 1992). Although microorganisms have tremendous variety, LPS and PGN are 
evolutionarily conserved and not expressed in higher eukaryotes, and as such, are ideal 
candidates for pattern recognition. Their distinct molecular-motifs provide a mechanism 
for highly-sensitive recognition by the pattern recognition receptor CD14. This allows the 
innate immune system to subdue and eliminate most infections quickly. 
CD14 plays an important role in the initiation of sepsis. Previous studies have 
revealed attenuation of the systematic response during sepsis by blocking CD14, and it 
has been inferred that the primary role of CD14 is to enhance the sensitivity of the 
endotoxin-induced signal for cel1ular activation. A precise molecular-level understanding 
of the CD14-endotoxin interactions is necessary to understand the pathogenesis of sepsis. 
LPS & PGN Induced Signal Transduction 
LPS and PGN induced intracellular signaling as part of the innate immune 
response is initiated by binding of CD14 to these endotoxins. CD14, however, lacks a 
transmembrane domain and is incapable of directly mediating the activation of signaling 
pathways within the cell. Instead, it associates with and presents the endotoxin to Toll-
like receptor (TLR), activating the ensuing intracellular signaling cascade. The Toll-like 
receptor family has 17 known members and consists of an extracellular leucine rich 
repeat (LRR) domain and a cytoplasmic TolllIL-lR (TIR) homology domain (Takeuchi 
& Akira, 2001). LRRs are short protein chains of 20 to 29 amjno acids found in a diverse 
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group of proteins that includes CD14 and myeloid differentiation protein 88 (MyD88). 
Due to the evolutionary conservation of LRR's in major pattern recognition proteins and 
receptors, the LRR is putatively thought to be important in the interaction of complexed 
CD14, TLR-4, and MyD88 (Kobe & Kajava, 2001). 
Upon endotoxin recognition by CD14, a legion of 
multiple signaling molecules are recruited and form 
receptor clusters on the cellular membrane (Fig 
2)(Triantafilou, 2003). The particular signaling 
proteins that must be recruited differ depending 
on which endotoxin has been detected. Activation of innate 
LPS induced defense pathways are enhanced by LBP, a 
60 kDa acute-phase protein that functions to transfer 
LPS to CD14 (Schumann et aI., 1990; Knapp et 
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aI., 2003). The LPS-CD14 complex 
primarily interacts with TLR-4 (Shimazu et 
aI. , 1999), though some studies suggest that 
Figure 2. CD14 mediated intracellular signaling 
cascade in response to endotox in detection. 
TLR-2 may playa role in LPS induced signaling as well(Yang et a!., 1998; Kirschning et 
aI., 1998). Although studies have shown that TLR-2 alone can activate the PON signaling 
cascade, heterodimers between TLR-2:TLR-1 or TLR-2:TLR-6 have also been suggested 
to associate with the PGN-CD14 complex (Ozinsky et aI., 2000). 
Though LPS and PON are both recognized by CD14, they stimulate different 
TLRs, TLR-4 and TLR-2 respectively (Wang et aI. , 2001). However, both TLR-4 and 
TLR-2 have similar signaling paradigms upon CD14 mediated activation. Though only 
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two requisite proteins have been linked with PGN activation of TLR-2, at least four 
proteins are necessary for the optimal cellular response to LPS: CDI4, LPS binding 
protein (LBP), Toll-like receptor 4 (TLR-4), and NID-2. The receptor cluster picture may 
not be so simple, however. Recently it was shown that TLR-4 when stimulated with LPS 
associates with a complex of receptors involving heat-shock proteins (hsp) 70 and 90, 
chemokine receptor 4 (CXCR4), and growth differentiation factor S (GDFS) (Triantafilou 
et aL, 2001; Triantafilou et aL, 2002). Additionally, MyD88 associates with TLR-4 and 
contributes responsiveness to LPS in some cells (Andreakos et aL, 2003). 
MD-2 is a secreted protein that interacts with the extracellular domain of TLR-4. 
The function of MD-2 has yet to be fully resolved. It has been suggested that MD-2 
induces a conformational change in TLR-4 necessary for the transport of the nascent 
protein from the endoplasmic reticulum to the cellular membrane (Nagai et al., 2002). A 
more plausible explanation is that MD-2 functions to improve TLR-4 binding sensitivity 
to LPS (Akashi et aL, 2000; da Silva Correia et aL, 2001). Two domains responsible for 
TLR-4 binding and LPS responsiveness have been identified on MD-2 by site-directed 
mutagenesis (Re & Strominger, 2003; Mancek et aL, 2002). The domain shown to 
increase LPS sensitivity is rich in aromatic and basic amino acids thought to interact with 
the negati veJy charged and hydrophobic regions of LPS (Re & Strominger, 2003). 
Upon LPS-induced activation ofTLR-4, the signal is transduced by 
phosphorylation of various adaptor proteins such as Myd88, IL-l receptor-associated 
kinase (IRAK), and tumor necrosis factor-associated factor-6 (TRAF6) (Guillot et aL, 
2003). A cascade of intracellular signaling ensues that in tum activates mitogen-activated 
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protein kinases (MAPKs), NF-KE-inducing kinase (NIK), and IKE kinase (IKK) 
(Hoffmann, 2002). Upon stimulation of IKK, IKE is phosphorylated and degraded. 
NF-KE is an inducible transcription factor that is constitutivly expressed in most 
cells. However, in cells at rest it is sequestered to the cytoplasm because it is associated 
with IKE. IKE signals for active transport out of the nucleus (Woronicz et aI., 1997). Only 
after IKE has been phosphorylated, ubiquitinated, and degraded is NF-KE active and able 
to effectively migrate to the nucleus (May et aI., 2002). NF-KE activation and migration 
into the nucleus results in the promotion of a cavalry of self-amplifying proinflammatory 
cytokines-IL-l, IL-4, IL-8, and TNF-a (Kopp & Medzhitov, 1999). Their release at the 
site of microbial invasion is the first step in the innate host response. This sophisticated 
innate armament allows for early detection and general defense against invading 
pathogens. 
Strategies for Treatment of Sepsis Involving CD14 
Previous treatment strategies in ICUs have involved the use of agents that block 
the activities of pro-inflammatory mediators, but have had limited success at decreasing 
the morbidity of patients (Glauser, 2000). In fact, clinical trials over the past 40 years 
including administration of polyclonal human antiserum against LPS, monoclonal 
antibodies against lipid A and TNF-a, and anti-coagulatory molecules have all failed to 
produce substantial improvements in patient mortality rates (Riedemann et aI., 2003). 
The new frontier of treatment strategies involves the design of antagonistic 
molecules that compete with microbial endotoxins by interacting with pattern recognition 
receptors, and the delineation of high-affinity compounds that bind endotoxins and 
8 
repress their ability to elicit an innate response. Potential targets include LBP, CDI4, 
TLR-2, TLR-4, TLR-6, and MO-2. It is important, however, that complete inactivation of 
proteins pivotal to innate immunity be avoided. 
CD14 may be an ideal candidate for treatment, as it confers sensitivity to several 
transmembrane signaling molecules. Currently, monoclonal antibodies against CD14 are 
being evaluated in phase II studies (Bochud & Calandra, 2003). CD 14-deficient mice 
were found to be highly resistant to shock induced by either live Gram-negative bacteria 
or LPS, while transgenic mice expressing human CD14 showed increased susceptibility 
to endotoxic shock and hypersensitivity to LPS (Haziot et aI., 1996; Ferrero et ai., 1993). 
Clinically blocking CD14 activity in cases of sepsis may represent a therapy that 
remedies the dysregulated inflammatory response without disrupting the overall ability of 
the innate immune system to fight the infection. However, without any structural data on 
the protein, rational drug design for this purpose is impossible. 
No X-Ray or NMR structural studies on 
CD14 have been conducted so far and the tertiary 
structure, essential for understanding the binding of 
CD14 to LPS and PGN, is not yet known. Further, 
no structure of a protein homologous CD14 exists 
either, preventing homology modeling. 
Mutagenesis and limited proteolysis studies have 
identified two regions on CD 14 thought to be 
responsible for binding LPS: residues 39-44 
(Stelter et aI., 1997) and residues 57-64 
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152 348 
Endotoxin Binding Leucine Rich 
Domain Region 
Full-length CD14 
Amino acid sequence of CD14 
M~~g~~f~;~t7d~L;'~Y~nVSAT TPEPCELDDE DFRCVCNFSE PQPDWSEAFQ 
CVSAVEVEIH AGGLNLEPFL KRVDADADPR QYADTVKALR VRRLTVGAAQ 
VPAQLLVGAL RVLAYSRLKE LTLEDLKITG TMPPLPLEAT GLALSSLRLR 
\ 
NVSWATGRSW LAELQQWLKP GLKVLSIAQA HSPAFSCEQV RAFPALTSLD 
152 --
LSDNPGLGER GLMAALCPHK FPAIQNLALR NTGMETPTGV CAALAAAGVQ 
LRR region 
PHSLDLSHNS LRATVNPSAP RCMWSSALNS LNLSFAGLEQ VPKGLPAKLR 
VLDLSCNRLN RAPQPDELPE VDNLTLDGNP FLVPGTALPH EGSMNSGVVP 
ACARSTLSVG VSGTLVLLQG ARGFA 
GPI anchor sequence 
Figure 3. CD14 sequence and motif diagram. The 
endotoxin binding domain was expressed and 
purified. 
(McGinley et al., 1995). Efforts to crystallize CD14 have been largely unsuccessful. 
NMR spectroscopy is an alternative method for structure determination. However, 
milligram quantities of CD14 are needed for NMR experiments. An efficient expression 
and purification protocol is necessary to obtain these amounts of protein and that too in 
isotopically labeled forms required for NMR structural studies. 
Materials & Methods 
CD14 20-171 Vector & Transformation into BL21-GoLd 
The coding sequence for CD14 from amino acids 20-171 was codon 
optimized for expression in E. coLi and synthesized (Bio ST). The resulting sequence was 
inserted into a pET30a vector (Novagen) between Xho I and Nde I restriction 
endonuclease sites such that only the C-terminal end would have the 6X-his tag. The N-
terminal His6 tag was not included because of its proximity to the functionally active 
portion of the protein. The pET30a plasmid confers kanamycin resistance to transformed 
cells for which it is compatible and contains an upstream lac operator for controlled 
induction of protein synthesis with IPTG. 
BL21-Gold(DE3) pLysS competent, chloramphenicol resistant cells from 
Stratagene were transformed after thawing on ice for 15 min. 3 J.ll, approximately 200 ng 
of plasmid DNA, was added to 35 J.ll of cells. After 10 minutes on ice, the solution was 
submitted to heat shock for 90 seconds at 42° C and then added to 35 J.ll of LB broth in a 
sterile Eppendorf tube. After incubation for 30 minutes at 37° C and 200 RPM, 35 J.ll 
were spread onto LB-Agar plates containing kanamycin and chloramphenicol to select 
transformed cells only, and incubated inverted at 37° C overnight. Single colonies were 
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picked for all growths. The BL21-Gold(DE3) pLysS strain of E. coli was selected 
because it encodes T7 Iysozome, a T7 RNA polymerase inhibitor. 
In order to ensure the purity of the vector DNA and reduce the frequency of 
nicked copies for optimal expression, the CD14 vector transformed BL21 cells were 
grown in 50 ml of LB broth for approximately 4 '12 hours, OD600 of .1-.2, and plasmid 
DNA was purified using a QIAprep Miniprep kit from Qiagen. To measure purity of the 
miniprep vector DNA, the absorbance was measured at 260 and 280 nm, and 2601280 
ratios between 1.6 and 1.8 were accepted as pure. 
Expression of soluble CD14 20-171 
For growth of transformed cells, 25g of LB, Miller powder from Fisher was 
dissolved per liter of distilled/deionized water. The solution was autoclaved for 25 
minutes, and cooled to room temperature before innoculation. Colonies from plates 
prepared as described above were transferred using sterile loops to 50 ml of flasks 
containing LB broth with kanamycin and chloramphenicol at concentrations of 50 and 35 
Ilg/ml, respectively. The cells were grown at 3T C with agitation of 200 rpm. Once the 
cells entered the log phase of growth, OD6oo of .3, they were transferred to larger shaker 
flasks. The cells were then grown to an OD600 of .6 before induction with 5 mM IPTG. 
After 3-4 hours, the cells were harvested by centrifugation at 6000 rpm for 15 minutes, 
and stored at -800 C until purification. Typical yields were 3-5 grams per liter of cells 
containing CD14 20-171 in the form of inclusion bodies which required resolubilzation. 
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Optimization of Resolubilization, Refolding & Purification of CD 14 20-171 
The frozen cells were resuspended in 50 mM Tris buffer pH 8.0 and stirred at 4° 
C for one hour. A cocktail protease inhibitor tablet (Roche) was added to prevent protein 
cleavage. In order to lyse the cells, the solution was sonicated for five 30 second bursts 
using a Branson Sonifier 450. 
PBS containing 6 M urea was originally used to resolubilize the CD14 20-171 
inclusion bodies. This refolding buffer when added to the lysate formed a highly viscous 
solution that hindered purification. Dilution of the solution 8 fold after the addition of 
urea did not resolve the problem. The solution remained viscous and clogged the Ni-NTA 
SuperfJow column (Qiagen) used for the purification of His6 tagged proteins. As a means 
of reducing the viscosity, a preliminary purification step was added to the protocol. 
Gravity columns were packed with anion-exchanging Sepharose 6B (Sigma-Aldrich). 
Although, flow-rates were initially higher, these columns eventually became congested as 
well. The loaded solution was then eluted with stepwise increments of increasing KCI 
concentration. The fractions of elutant containing CD14 were then successfully loaded 
onto the Ni-NTA column (Qiagen), however only small quantities of CD14 were purified 
in this fashion. 
As an alternative, the viscous 6M urea lysate solution was subjected to 
ultracentrifugation at 50,000g. This cleared the lysate considerably and was followed by 
passing the supernatant through .44 ~m Stericup filters (Millipore). After 
ultracentrifugation and filtration, the cleared lysate passed easily over Ni-NTA columns. 
This purification method effectively produces CD14 20-171, however it is taxing and 
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requires the use of several Stericup filters. An effective alternative in which 
resolubilation by addition of 6 M GuHCI is described below. 
For resolubilization of inclusion bodies, guanidine hydrochloride was added to the 
lysed cell suspension to make it 60% by weight, and the solution was stirred at 4° C for 1/2 
hour. Afterwards, the solution was centrifuged for 30 minutes at 12,000 rpm. The 
supernatant was then diluted 6 fold in refolding buffer (50mM Tris pH 8, 2M glycine, 
5mM cysteine) and stirred over-night. The solution containing the solubilized and 
refolded CD14 20-171 was then centrifuged for 30 minutes at 12,000 rpm to remove any 
precipitated debris. Ammonium sulfate precipitation was then performed at 60% by 
weight to further purify the protein, and the resulting pellet was dissolved in phosphate 
buffer saline (PBS), pH 8. 
Gravity flow columns packed with Ni-NTA Superflow from Qiagen were then 
loaded with the CD14 solution and washed with 100 ml PBS followed by 50 ml of PBS, 
25 mM imidazole. The bound CD14 was eluted with PBS containing 250 mM imidazole, 
and the elutant was concentrated in amicon Centripreps (MWCO 10,000) from Millipore 
to a volume less than 1m!' 
Gels and Western Blotting 
PhastGel Homogenous 20% gels from Amersham Biosciences were used to run 
purified samples of CD14 20-171. The gels were silver-stained and developed with 
formaldehyde. Prior to running the samples, they were boiled for 10 minutes in SDS and 
~-ME. The BioRad Precision Plus Protein Dual Color ladder was used to consistently 
mark the CD 14 peak. 
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Western blots were perfonned after boiling the samples in a denaturing, non-
reducing buffer containing SDS. Novex pre-cast gels, 18% Tris-Glycine from Invitrogen 
were used. 15111 of SDS-boiled sample solution were loaded per well, and gels were run 
at 125V for 11/2 hours in an Xcell SureLock Mini-Cell electrophoresis unit from 
Invitrogen. After seperation, an Xcell II Blot Module was used to transfer the protein to a 
PVDF membrane at 25V for 1 Y2 hours. A Tris based solution containing 5% milk, .1 % 
Tween was used to block the membrane. Membranes were blocked overnight at 4° with 
slow agitation. Primary and secondary antibodies were added and incubated for 1 hour at 
room temperature each. Mouse monoclonal human anti-CDl4 (ab8103) from Novus was 
diluted 1 :400 and used as the primary antibody for CD 14 detection with an HRP 
conjugated anti-mouse polyclonal secondary. Additionally, HRP conjugated mouse 
monoclonal His6 (ab7857) from Novus was diluted 1 :4,000 and used to detennine that 
the entire protein and His6 tag had been expressed. CNIDAB precipitating substrates 
from Pierce were used to develop the bound HRP conjugated antibodies. 
Results & Discussion 
Analysis of the primary structure of CD14 shows that the carboxy tenninal 
end of CD14 consists of 10 leucine rich repeats (Fig 3), of which 7 leucine rich repeats 
are predicted to be involved in interactions with TLRs and other signaling molecules . 
Additionally, the first 19 amino terminal residues are a signal peptide that is cleaved 
before the protein leaves the endoplasmic reticulum. The functional region of the protein 
that recognizes and binds endotoxins is located within the first 152 N-tenninal amino 
acids after the signal peptide region. Therefore, for ligand binding and structural studies 
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of CD14, residues 20-171 would be appropriate for expression. Shorter fragments of N-
terminal CD14 would be subject to protease degradation and were therefore not 
considered. E. coli was chosen as an expression system 
for CD14 since the use of mammalian cells is unlikely 
to generate sufficient quantities of CD 14 for NMR 
based structural studies. Expression of CD14 in yeast 
has been characterized, however, protein glycosylation 
occurs which presents a problem for NMR studies due 
to the presence of multiple conformations as a result of 
glycosylation. 
Figure 4. SDS-Page analysis of 
partially purified CD 14. Arrows show 
the CDI4 band 
CD14 20-171 expression in E. coli using the pET30a expression system was 
successful. Yields of CD14 were improved when cultures were inducted at an OD600 of 
.6. When grown to higher concentrations before induction, the yield of cells was greater, 
but less total protein was produced. Figure 4 shows that CD14 20-171 migrated with the 
20 kDa marker in the PhastGels confirming expression of protein with correct molecular 
weight. Expression using the protocol described here results in production of about 1-2 
mg of protein/liter of medium. Western blotting results show that anti-human CD14 
monoclonal antibody (Novus-ab8103) does bind to N-terminal residues 20-171 when 
transferred to PVDF membrane from SDS, non-denaturing gels (Fig 5). It has been 
reported that some CD14 antibodies do not recognize CD14 when ran in SDS-PAGE 
conditions (Majerle et aI., 1999). 
Our recombinant CD14 contains 4 Cysteine residues, and their redox state must 
be controlled for proper refolding. This is effectively accomplished by the addition of 5 
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mM cysteine to the refolding buffer. Resolubilization of inclusion bodies by addition of 
urea is cumbersome and presents many problems associated with the high viscosity of the 
solution. Guanidine hydrochloride is an effective alternative for resolubilizing the 
protein. The ammonium sulfate precipitation is an essential step that contributes greatly 
to the purification protocol. After dissolving the precipitated protein, the CD14 solution is 
clear and roughly 50% pure. The CD14 sample purity is increased to approximately 70% 
following elution from the Ni-NTA column. To achieve the greater than 95% purity 
necessary for acquiring NMR spectra with a high signal to noise ratio, the sample will be 
run on a molecular size exclusion column. 
Although studies indicate that endotoxin binding takes place between residues 39-
64 (Stelter et aI., 1997; McGinley et aI., 
1995; Juan et aI., 1995), attempts at 
expressing fragments of CD14 much 
shorter than 152 residues have been 
unsuccessful (Majerle et aI., 2000). 
Shorter fragments may not form a 
compact domain and be rapidly 
degraded upon translation. Therefore, 
for ligand binding studies of CD14, 
residues 20-171 were chosen . Bacterial 
, 
1 2 3 4 1 2 3 4 
CDI4 CDI4 
A B 
Figure 5. Western blots confirming CD14 expression 
by using a-CD 14 10 (A) and translation of entire 
protein and His6-tag by using a-His6 10 (B). Lanes 
1 & 2 in each blot are from preps induced at OD of .6; 
Lane 3 was induced at OD 1.2. 
expression of CD14 is quick and scaleable, however, one caveat is that many strains of 
bacteria possess LPS , a natural ligand of CD14, and care must be taken not to 
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contaminate the sample of purified protein. This problem is avoided in part by expressing 
the CD14 in inclusion bodies. 
Not only does bacterial expression of CD14 produce milligram quantities of 
protein required for structural studies in NMR, but the protocols used for unlabeled 
expression are easily applied to isotopic labeling of the protein. E. coli BL21 cells grow 
and express well in minimal media which allows for unproblematic 13C and lSN 
incorporation into the protein backbone and sidechains, which is necessary for high 
resolution of NMR spectra. 
As the progression of sepsis is intimately linked with the induction of several 
endotoxin-activated signaling cascades, describing its pathogenesis is exceedingly 
complex. CD14 is an ideal candidate for therapy designed to suppress the progression of 
sepsis because it confers sensitivity to multiple transmembrane signaling molecules that 
are responsible for detection of an array of endotoxins. Although several eloquent 
mutagenesis studies have identified epitopes of CD14 responsible for endotoxin binding 
and monoclonal antibodies that competitively bind CD14 developed, no sophisticated 
structural studies have been conducted on the protein. The shortcomings of current 
treatments of sepsis can be overcome once the structure-function relationships are 
determined by NMR spectroscopy. Rational drug design can be accomplished by 
identifying high-affinity ligands of CD14 that antagonize the effects of endotoxins by 
performing NMR binding studies. 
NMR binding studies will resolve the nature of the binding, identifying the 
precise residues interacting on CD14 and the binding portions on the endotoxin ligands. 
17 
However, for this to be possible, expression of sufficient quantity of protein is required, 
which has been accomplished during the course of this work. 
18 
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